在抗化学性白血病细胞中,CADM1损害了miR-1246对促进细胞循环进展的作用
Bei Xie1, Lei Zhao2, Zhewen Zhang3
1Department of Immunology, School of Basic Medical Sciences, Lanzhou University, No. 199 Donggang West Road, Lanzhou, 730000, Gansu, China. xieb@lzu.edu.cn.
BMC cancer
|October 9, 2023
概括
微RNA-1246 (miR-1246) 通过抑制调节细胞循环进展的CADM1来促进白血病药物耐药性. 抑制miR-1246或恢复CADM1可以提高白血病的化疗敏感性.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 遗传学 是一个遗传学.
背景情况:
- 异常的细胞循环调节对于白血病的发展至关重要.
- 微RNAs (miRNAs) 与癌症有关,其失调的表达影响了瘤发生.
- 我们之前的工作确定了miR-1246在抗化疗白血病中的过度表达,将其与细胞周期和多药物耐药性联系起来.
研究的目的:
- 阐明miR-1246影响白血病化学耐药性的机制.
- 确定参与白血病进展的miR-1246的直接标.
- 为了研究针对miR-1246/CADM1轴的治疗潜力.
主要方法:
- 生物信息学预测和双 luciferase 报告员测试以确定 miR-1246 的目标.
- 在患者样本和细胞系中分析CADM1表达.
- 在K562/ADM和HL-60/RS细胞中进行功能测试,以评估miR-1246抑制和CADM1干扰对药物敏感性,细胞循环和亡的影响.
- 研究CDKs/Cyclins复合体在调解这些效应中的作用.
主要成果:
- 证实CADM1是miR-1246.6的一个直接目标.
- 在复发性白血病患者和化疗耐药细胞系中,CADM1的表达显著下降.
- 抑制miR-1246增强了阿德里亚米辛的敏感性,诱导了G0/G1细胞循环停止,促进了细胞亡,并恢复了CADM1的表达.
- CADM1干扰逆转了由miR-1246抑制引起的增强药物敏感性,通过细胞周期调节促进化疗耐药性.
结论:
- 通过减弱miR-1246的亲生存和细胞循环促进作用,CADM1起到瘤抑制作用,在抗化疗白血病中发挥作用.
- 涉及CDKs/Cyclins的miR-1246/CADM1轴是白血病中多药耐药性的关键调节者.
- 升高的miR-1246和降低的CADM1表达是白血病进展和化疗耐药性的潜在危险因素.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Separation of Sister Chromatids
3.7K
At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
At the onset of anaphase, separase, a proteolytic enzyme, is...
3.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


